Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp (NQ: LEXX )

2.765 +0.035 (+1.28%)
Streaming Delayed Price Updated: 11:44 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,243
Open 2.640
Bid (Size) 2.750 (1)
Ask (Size) 2.790 (22)
Prev. Close 2.730
Today's Range 2.640 - 2.800
52wk Range 0.7598 - 6.850
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
+114.34%
+114.34%
1 Month
+2.79%
+2.79%
3 Month
+22.08%
+22.08%
6 Month
+81.31%
+81.31%
1 Year
+225.29%
+225.29%

More News

Read More
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
Via ACCESSWIRE
Lexaria Preparing For Strategic Growth
Via ACCESSWIRE
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Issuance of Three New Patents, Growing Portfolio to 46 Granted Patents Worldwide
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award for 12-Week Chronic Human Study
Via Investor Brand Network
LEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024
Via InvestorPlace
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
Via ACCESSWIRE
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
Via ACCESSWIRE
Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures New Patents for Antiviral Drug Delivery, Treating Epilepsy
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Favorable Strategic Partnering with Leading GLP-1 Players
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2; Set to Complete Third Study Arm in Early July
Via Investor Brand Network
7 A-Rated Penny Stocks to Beat June Gloom
Via InvestorPlace
HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Engages CRO for DehydraTECH GLP-1 Human Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO; Set for First Tirzepatide Molecule Study
Via Investor Brand Network
7 A-Rated Biotech Stocks Worth Betting on in June
Via InvestorPlace
Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.